Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sec. 301 branding provisions on chopping block?

This article was originally published in The Gray Sheet

Executive Summary

Oct. 29, the Senate HELP Committee's last scheduled mark-up date, may provide OEMs with their final opportunity this year to secure technical corrections to MDUFMA clarifying that inclusion of a manufacturer's name, abbreviation or symbol should apply only to single-use device reprocessors, not to OEMs. Without the legislative fix, advocated in several industry comments to FDA, the agency will be hard pressed to develop branding guidance, according to CDRH staffers. In June, FDA released a 1draft guidance indicating an 18-month grace period would be attached to the final guidance release date (2"The Gray Sheet" June 23, 2003, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel